Finland’s CurifyLabs raises $14M to 3D-print personalised medicine in the US

Your prescription, printed to order. A Finnish startup wants to turn the back room of your pharmacy into a tiny, automated drug factory, and it just raised $14m to do it in America.

CurifyLabs has closed a $14m (€12m) Series A, the company announced. The Helsinki firm makes machines and software that let pharmacies 3D-print personalised medicines on site. The money will push it deeper into the United States, where its kit already runs in pharmacies across 21 states.

Medicine, made to measure

Most pills come in fixed doses. But children, elderly patients and people with rare conditions often need something in between, or a different form entirely. Pharmacists have long made these by hand, a slow and error-prone job called compounding.

CurifyLabs automates it. Its system pairs software with pharmaceutical-grade ingredient bases and a 3D printer to produce tailored doses with built-in quality checks.

Its newest printer, the PharmaPrinter Aurum, compounds up to nine times faster than doing it by hand, the company says. The technology is ISO 13485 certified and built to meet the US FDA’s rules for non-sterile compounding.

The 💜 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!

A Nordic bet on the US market

Sandwater and HealthCap co-led the round, with Finland’s state investor Tesi and existing backer Lifeline Ventures taking part. Some US customers and staff chipped in too. The proceeds go to US expansion, supply chain, customer support and research.

“Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage,” said Joni Karsikas of Tesi. It is a familiar Nordic ambition. Espoo’s IQM just listed in New York, and the region keeps sending its deep-tech firms across the Atlantic.

Small round, big frontier

Founded in 2021 by chief executive Charlotta Topelius and pharmaceutical scientist Niklas Sandler, CurifyLabs raised this on top of a €6.7m round last year. The sum is small against a pharma market worth trillions. Automating the messy edges of it is a real business, though.

Others chase the same shift, from pharmacist-free dispensaries and a wave of European drug-tech funding to big public precision-medicine projects. Personalised medicine has been “almost here” for years. CurifyLabs is betting that, dose by printed dose, it finally arrives.